Neurotech

INVESTOR WEBINAR PRESENTATION

August 2021

BRIDGING TO A BETTER LIFE

Disclaimer

IMPORTANT INFORMATION

Purpose of presentation: This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech International Limited (ACN 610 205 402) (**Neurotech** or **Company**). It has been prepared for the sole purpose of providing general information on Neurotech and its business.

Not an offer or solicitation: This presentation is not investment advice nor an offer to subscribe for securities or otherwise invest in Neurotech, and it should not be relied upon to make any investment decision. Further, it does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of securities pursuant to this presentation in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful under applicable law, including the Securities Act of 1933 (USA), as amended (**US Securities Act**). Securities have not been registered under the US Securities Act or any US state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the US Securities Act and applicable state securities laws.

Not a prospectus: This presentation is not a prospectus, product disclosure statement or other investment disclosure document, and the level of disclosure in this presentation is less than such disclosure documents. It has not been lodged with any regulatory or supervisory body. This presentation does not purport to contain all of the information that a prospective investor may require to make an evaluation of Neurotech or its business activities and nothing in this presentation is, or is intended to be, a recommendation to invest in Neurotech. Neurotech does not purport to give financial or investment advice. Account has not been taken of the objectives, financial situation or needs of any recipient of this presentation.

Forward-looking statements: This presentation contains forward-looking statements which may be predictive in nature and incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets' or 'expects'. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events.

These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that many of the events are outside Neurotech's control. The stated events may differ materially from results ultimately achieved. Accordingly, neither Neurotech nor any of its directors, employees, contractors or advisors make any warranty or assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur. Further, other than as required by law, Neurotech may not update or revise any forward-looking statement if events subsequently occur or information subsequently becomes available that affects the original forward-looking statement.

Disclaimer: Neither Neurotech nor its officers, employees, contractors or advisers make any warranty (express or implied) as to the accuracy, reliability, relevance or completeness of the material contained in this presentation. Nothing contained in this presentation is, or may be relied upon as a promise, representation or warranty, whether as to the past or the future. Neurotech excludes all warranties that can be excluded by law. Except for statutory liability which cannot be excluded, Neurotech, its officers, employees, contractors and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in this presentation and exclude all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Professional advice: Recipients of this presentation should consider seeking appropriate professional financial, taxation and legal advice in reviewing the presentation and all other information with respect to Neurotech and evaluating its business, financial performance and operations.

Proprietary information and copyright: This presentation and the information it contains is proprietary to Neurotech. Neurotech holds the copyright in this presentation. Except as permitted under the Copyright Act 1968 (Australia), this paper or any part thereof may not be reproduced without its written permission.

Unique Value Proposition

Neurotech is focussed on the development & commercialisation of neurological solutions that improve quality of life

Neurotech has exclusive worldwide licence to utilise proprietary cannabis strains from Dolce Cann Global Pty Ltd ('Dolce') for all neurological disorders

Dolce Cann Global cannabis strains contain naturally low levels (<0.3%) THC. High levels of CBD-A, CBG, CBN, CBD-B, CBD-P

Potential for the NTI/Dolce cannabis strains to treat neurological disorders including autism, epilepsy, MS & ADHD

Neurotech has completed extensive preclinical studies with human clinical trials underway

Commencement of world's first whole plant extract cannabis clinical study in autistic children with little to no THC and unique cannabinoids

Neurotech's Mente device & therapy is clinically proven to increase engagement & improve relaxation in autistic children with elevated delta band brain activity

Mente continues to gain recognition as a therapeutic tool with parents and carers of those with autism spectrum disorder

Corporate Overview

CAPITAL STRUCTURE	
Share price (as at 4 August 2021)	$0.05
Shares on issue	696m
Options	113m^
Cash at bank*	~$4.83m
Market capitalisation	~$35m

^Options have various strike prices between $0.005 to $0.09
*As at 30 June 2021

Highly Experienced Board

Brian Leedman
Chairman

- More than 15 years' experience in the biotechnology sector
- Founder / co-founder of five ASX listed healthcare/ biotechnology companies including: RAP, NGS, NSB, OSL, IMU
- Former Chairman of Ausbiotech (WA)
- BEc, MBA (UWA)

Krista Bates
Non-Executive Director

- Experienced director of ASX and LSX companies
- More than 20 years' experience in legal practice
- Former Partner at leading law firm, Lavan Legal – Head of the Medical Cannabis Group
- BA(Hons), Grad Dip (Law), PostGrad Dip (Law), GAIDC

Prof. Allan Cripps AO
Non-Executive Director

- Distinguished academic, clinical scientist and health services leader
- Independent Chair of the Children's Health Research Alliance Board and Non-Executive Director at Bard1 (BD1)
- Formerly the Pro Vice Chancellor (Health) at Griffith University and currently professor emeritus at Griffith University
- PhD, BSc (Hons), FAHSM, FASM, FAIMS, FIBMS, FCHSM, MACID

Mark Davies
Non-Executive Director

- More than 20 years' experience in trading, investment banking & providing corporate advice
- Specialises in providing corporate advice & capital raising services to emerging companies seeking business development opportunities and funding from the Australian market
- Managing Director of 1861 Capital and co-founder of investment banking firm, Cygnet Capital
- BCom

Winton Willesse
Non-Executive Director

- Experienced company director with over 20 years experience in various roles within the Australian capital markets
- Core expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance
- MCom, FFin, CPA, GAICD, FGIA/FCG

Medicinal Cannabis industry is only just getting started

There are only four approved cannabis based drugs

FDA

- *Marinol® (dronabinol)* synthetically manufactured (CBD | THC) and registered in the US by the Food and Drug Administration (FDA) for the treatment of anorexia in patients with AIDS and for the management of chemotherapy-induced nausea and vomiting where standard anti-nausea treatments have failed.
- *Cesamet® (nabilone)* synthetically manufactured (CBD | THC), and registered in the US by the FDA for the management of chemotherapy-induced nausea and vomiting.

TGA

- *Epidyolex®* is approved for adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) for patients 2 years of age and older.
- *Sativex®* is approved for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.





Source: www.grandviewresearch.com

Global drug market size for neurological disease



1 - Transparency Market Research
2 – businesswire.com
3 – Brand Essence Research
4 – Allied Market Research
5 – Coherent Market Insights

NTI/Dolce strains have unique properties compared to CBD alone

- Very high levels of CBD-A (primary active) – studies have confirmed that CBD-A up to 1,000 times more potent in regulating inflammation in chemotherapy patients than CBD alone.
- Recent studies have indicated that CBD-A can cross the blood-brain barrier.
- Regulate and supress inflammation by acting on Arginase1, powerful anti-inflammatory enzymes and therefore potential to be a powerful anti-inflammatory agent.
- Up-regulating and modulation of the of beta-tubulin protein, an essential protein in the maintenance and healthy survival of brain cells.
- Suppress and modulate the activity of iNOS – which is directly involved in the complex cytokine pathways relating to immunity and natural defence mechanisms.



- Preclinical studies have demonstrated that NTI/Dolce strains (<0.3% THC) exhibit powerful anti-inflammatory, neuro-protective and neuro-modulatory properties – full entourage effect, which are much more powerful than CBD alone.
- NTI/DOLCE's strains have multi-functional activities across multiple pathways – to date CBD alone has only targeted one specific pathway.
- Naturally occurring low levels of THC make the NTI/DOLCE strains accessible to paediatric patients and others looking to avoid the "High" effect.
- Preclinical results to date show that NTI/DOLCE strains have unique modes of action when compared to CBD alone.

Results from Pre-clinical Studies

Studies were designed to assess the **neuroprotective** and **neuro-modulatory** activities of the top DOLCE/NTI cannabis strains.

Studies were conducted in human derived brain and muscle cells – these models are internationally accepted and used to assess the efficacy and mechanism of neurological actives.

Key Findings

In all studies the top DOLCE/NTI strains demonstrated superiority when compared to CBD alone.

- DOLCE/NTI strains demonstrated reduction in brain cell inflammation (up to 60%)
- DOLCE/NTI strains demonstrated an increase in overall brain cell health and viability (in the absence of toxic insult up to 80%)
- DOLCE/NTI strains demonstrated an increase in mitochondrial viability and output (in the presence of toxic insult up to 60%)
- DOLCE/NTI strains demonstrated significant suppression of neuro-markers linked to MS (GM-CSF < 40% and TNF-alpha < 30%)

Inflammation, cell and mitochondrial viability are all very important processes and outcomes in understanding, maintaining brain function and cognitive health.

Results clearly demonstrate the powerful neuroprotective and neuro-modulatory properties of the DOLCE/NTI strains and superiority when compared to current market standard: **CBD isolate**

Studies pave the way forward in designing the optimum clinical design program and clinical indication/s.

Expected pathway of cannabis project

1. In vitro assay assessments

Neuronal or muscle cell line assessments

Analytical assessments & validation program to be completed in collaboration with Monash University, RMIT University and University of Wollongong. These studies are to assess:

- Dose response studies
- Upper level of toxicity assessments
- Mechanism of action profiling
- Selection of top candidates

COMPLETED

2. Product formulation and final dose profiling

To be conducted in collaboration with Cannabis Formulation Experts and ACS Laboratories

Final product application: i.e. Spray, tincture, oil

Final specification sign off

COMPLETED

3. Phase I/II Human safety & efficacy clinical trials

Commenced in May 2021 in at Monash Children's Hospital a leading Australian University led by A/Prof. Michael Faye

- Open label – single group
- 20 patients from 5 to 17yo
- 16 week duration including 4 week washout period
- Assess key behaviours changes
- Submission to the TGA and relevant regulatory bodies

Why target Autism Spectrum Disorders (ASD)?

- ASD is a serious neuro inflammatory developmental disorder that impairs the ability to communicate and interact
  - Range and severity of symptoms can vary widely
  - Common symptoms include; behavioural issues, agitation, repetitive movements, inability to focus and compulsive neurological patterns

- Huge unmet medical need - patients need better treatment options without side effects
- Limited options are available to children
- *$4b US annual sales from market leading medications; Ritalin and Concerta (active ingredient Methylphenidate)
- Both medications have numerous side effects including:
  - Appetite loss, dry mouth, anxiety, irritability, nausea, insomnia, abdominal pain, weight loss, dizziness and heart palpitations
  - Parents and carers often stop using these medications due to their side effects profile

- Since 2017, studies with medicinal cannabis (CBD + THC) have shown some promise in children with ASD

- To date there have been no studies assessing medicinal cannabis with low (<0.3%) THC in the treatment of ASD
- NTI is conducting the first study of its kind to assess medicinal cannabis rich extract with low THC in children with Autism

*https://clincalc.com/DrugStats/Drugs/Methylphenidate

Pathways to commercialisation

The anti-inflammatory properties NTI Dolce strains in combination with minimal presence of THC (< 0.3%) provides three clear pathways to commercialisation:



Strategic Partners

Monash Children's Hospital
A/Prof Michael Fahey – Head of Neurology
Professor Katrina Harris – Head of Paediatrics

Victorian College of Pharmacy
Department: Centre for Medicinal Chemistry

ACS Laboratories | Melbourne Australia
TGA Approved Cannabis Testing Facility

BJP Laboratories, Brisbane Australia
Unit: Formulation and Development Group

RMIT | Melbourne Neurodevelopment in Health and Disease

Walter and Eliza Hall Institute | Melbourne
Department: Cellular and Molecular Biology

Canna Pacific | Australia
Fully approved ODC Facility – NSW

Hemp Masonry | NSW – Growing Advisory Services

Althea Life Pharmaceuticals | Cannabis Breeding Services - Vic, Australia

Expected news flow



Preclinical

Expansion of Preclinical programme into wider neurological indications – June 2021

Further results

Further Preclinical results in MS – June 2021

Interim results

Interim results on Phase I/II clinical study in Autism – July 2021

Final results

Final results on Phase I/II clinical study in Autism – Q4 calendar 2021

Expansion

Expansion of Phase II clinical study in Autism – Q4 calendar 2021

Multi-cohort Phase

Multi-cohort Phase III Registration Trials in Autism – Q1 calendar 2022

Neurotech

Neurotech International Limited (ASX: NTI)

CONTACT DETAILS

Brian Leedman
Chairman
b.leedman@neurotechinternational.com
+61 412 281 780

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 410 667 844

This presentation has been authorised for release by the Board of Neurotech International Limited.

www.neurotechinternational.com
www.mentetech.com